The CWRU/UHC CFAR has established a unique research program with key strengths in intemational research, ITuberculosis, clinical/translational research and in training. A 16 year close collaboration between CWRU and Makerere IUniversity in Uganda has a fostered an effective HIV research infrastructure in Kampala. An effective Fogarty AIDS pntemational Training and Research Program (AIRTP) with at least 30 degree graduates now working in Africa has also promoted an enhanced level of HIV research, HIV care and prevention in Uganda. In Cleveland and Uganda, through the Tuberculosis Research Unit, key studies of epidemiology, pathogenesis and therapy for this leading co-morbid infection late also undertaken by the CFAR. CWRU investigators also are leading novel NCI-sponsored trials of chemotherapy fow I/kiDS-related malignancy in Uganda and Kenya. The CWRU/UHC CFAR has also developed one of the most productive Iclinicalcores in the CFAR network that has supported more than 120 separate clinical and translational research projects Idudng this period of award because of its unique and patient-care/research data base, a linked specimen repository an_ seamless access to patient volunteers and clinical samples rrhe CFAR leadership (Steering Committee) that comprises both the Core Directors and leaders of 7 scientific working groups assures that scientific needs and directions of the Center are coordinated with service needs and resources. Six CFAR service cores are each designed to provide CWRU investigators with user-friendly access to state of the art services and facilities both in Cleveland and in Kampala. These cores: Uganda Laboratory, Clinical, Biosafety, Immune Function, Epidemiology/Biostatistics and the new Molecular Virology and Gene Expression are led by expedenced investigators and provide quality services that include on-site training and range from access to instrumentation for experienced users to full service performance of assays for infrequent users to meet investigators'individual needs. Ar Administrative Core coordinates and supports CFAR activities through communications, reporting, accounting ant outreach. A Developmental Core provides support and training for new researchers, which is supplemented by generou., institutional funding. Strong institutional support is reflected in a nearly $15 million commitment by CWRU and UHC to the CFAR. The CFAF provides added value to the national and international AIDS research effort through its provision of scientific leadership infrastructure dedicated to AIDS research that provides facilities and resources, including some that are not available a other CFARs, and well-oganized sponsorship of training, education and outreach.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036219-16A1S1
Application #
8093104
Study Section
Special Emphasis Panel (ZAI1-JBS-A (J1))
Program Officer
Namkung, Ann S
Project Start
2010-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
16
Fiscal Year
2010
Total Cost
$121,129
Indirect Cost
Name
Case Western Reserve University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286

Showing the most recent 10 out of 539 publications